Anzeige
Mehr »
Donnerstag, 28.08.2025 - Börsentäglich über 12.000 News
Patentschutz bis in die 2040er - Biotech-Geheimtipp vor möglichem Fast-Track-Durchbruch in den USA!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PGL8 | ISIN: US14817C1071 | Ticker-Symbol: PX91
Tradegate
27.08.25 | 15:52
1,985 Euro
+2,45 % +0,048
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CASSAVA SCIENCES INC Chart 1 Jahr
5-Tage-Chart
CASSAVA SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,9602,02027.08.
1,9752,02227.08.

Aktuelle News zur CASSAVA SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.08.CASSAVA SCIENCES INC - 10-Q, Quarterly Report4
14.08.Cassava Sciences GAAP EPS of -$0.926
14.08.CASSAVA SCIENCES INC - 8-K, Current Report2
14.08.Cassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business Update541Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced...
► Artikel lesen
07.08.Cassava Sciences Appoints Joseph Hulihan As New Chief Medical Officer3
CASSAVA SCIENCES Aktie jetzt für 0€ handeln
07.08.Cassava Sciences appoints Joseph Hulihan as chief medical officer1
07.08.Cassava Sciences, Inc.: Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer108Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related...
► Artikel lesen
04.08.CASSAVA SCIENCES INC - 8-K, Current Report22
04.08.Cassava Sciences, Inc.: Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy213Study in a TSC mouse model further demonstrates simufilam's anti-seizure activityStudy conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout modelFirst clinical study for...
► Artikel lesen
30.06.Cassava Sciences reports simufilam reduced seizures in mouse model35
30.06.CASSAVA SCIENCES INC - 8-K, Current Report8
30.06.Cassava Sciences, Inc.: Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting6
28.05.Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit58
08.05.CASSAVA SCIENCES INC - 10-Q, Quarterly Report27
08.05.CASSAVA SCIENCES INC - 8-K, Current Report10
21.04.Cassava Sciences appoints new SVP of Clinical Development13
21.04.Cassava Sciences ernennt neuen SVP für klinische Entwicklung14
21.04.CASSAVA SCIENCES INC - 8-K, Current Report3
21.04.Cassava Sciences, Inc.: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development282AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational...
► Artikel lesen
30.03.Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus35
Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,2,8